- Rawat, M, Boonyalai, N, Smidt, C, Luth, MR, Chen, D, Plater, A et al.. Mechanistic Insights into Dual-Active Liver and Blood-Stage Antiplasmodials. bioRxiv. 2025; :. doi: 10.1101/2025.08.06.666330. PubMed PMID:40799604 PubMed Central PMC12340835.
- Wicht, KJ, Woodland, JG, Garnie, LF, Langeveld, H, Taylor, D, Godoy, LC et al.. The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against Plasmodium falciparum via Dual Inhibition of PfArk1 and Hemozoin Formation. bioRxiv. 2025; :. doi: 10.1101/2025.07.17.664511. PubMed PMID:40791395 PubMed Central PMC12338603.
- Nardella, F, Jiang, T, Wang, L, Bohmer, MJ, Chakraborty, S, Okombo, J et al.. Plasmodiumfalciparum protein kinase 6 and hemozoin formation are inhibited by a type II human kinase inhibitor exhibiting antimalarial activity. Cell Chem Biol. 2025;32 (7):926-941.e23. doi: 10.1016/j.chembiol.2025.06.003. PubMed PMID:40628257 PubMed Central PMC12406260.
- Probst, AS, Paton, DG, Appetecchia, F, Bopp, S, Adams, KL, Rinvee, TA et al.. In vivo screen of Plasmodium targets for mosquito-based malaria control. Nature. 2025;643 (8072):785-793. doi: 10.1038/s41586-025-09039-2. PubMed PMID:40399670 PubMed Central PMC12267055.
- Godinez-Macias, KP, Chen, D, Wallis, JL, Siegel, MG, Adam, A, Bopp, S et al.. Revisiting the Plasmodium falciparum druggable genome using predicted structures and data mining. NPJ Drug Discov. 2025;2 (1):3. doi: 10.1038/s44386-025-00006-5. PubMed PMID:40066064 PubMed Central PMC11892419.
Search PubMed